Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant intravesical mitomycin before TURB to prevent recurrence in non–muscle-invasive urothelial carcinoma
2017-004070-34Phase 4Active
- Sponsor
- Servicio de Urología
- Start
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mitomycin c in urothelial carcinoma (UC) (2 arms), sponsored by Servicio de Urología. Primary endpoint: Rate of early recurrence of non–muscle-invasive urothelial carcinoma. Started Nov 2017; status: active.
02
Drugs
mitomycin c
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on 2017-004070-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004070-34.